Clinical efficacy and safety of second-line cabozantinib after first-line immune checkpoint inhibitor-based combinations in metastatic renal cell carcinoma: a multicenter retrospective study. (PubMed, Int J Clin Oncol) - Oct 9, 2026 - "Second-line cabozantinib provided meaningful efficacy across all approved first-line ICI-based combinations. Cumulative PFS from first-line therapy initiation was similar across regimens, although OS data for the Pem + Len group remain immature. Cabozantinib appears to represent a reasonable second-line option in the ICI era."
Checkpoint inhibition • Journal • Retrospective data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
Akira Nagahara; Atsuki Matsukawa; Atsunari Kawashima; Eisuke Tomiyama; Hitoshi Takayama; Jiro Nakayama; Kazutoshi Fujita; Kensaku Nishimura; Koichi Okada; Koji Hatano; Lan Inoki; Masaharu Oki; Masashi Nakayama; Mototaka Sato; Norio Nonomura; Ryoichi Imamura; Shingo Takada; Taigo Kato; Takahiro Imanaka; Takahiro Maekawa; Takuji Hayashi; Tetsuya Takao; Yoshiyuki Yamamoto; Yu Ishizuya; Yutaka Ono
|